CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$54.88 USD
+0.32 (0.59%)
Updated Jul 22, 2024 01:10 PM ET
1-Strong Buy of 5 1
F Value C Growth B Momentum D VGM
CRISPR Therapeutics AG (CRSP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$86.95 | $199.00 | $30.00 | 59.37% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for CRISPR Therapeutics AG comes to $86.95. The forecasts range from a low of $30.00 to a high of $199.00. The average price target represents an increase of 59.37% from the last closing price of $54.56.
Analyst Price Targets (22)
Broker Rating
CRISPR Therapeutics AG currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms. The current ABR compares to an ABR of 2.17 a month ago based on 27 recommendations.
Of the 28 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 46.43% and 3.57% of all recommendations. A month ago, Strong Buy made up 48.15%, while Buy represented 3.7%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 11 | 11 | 10 | 10 | 10 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.20 | 2.20 | 2.17 | 2.17 | 2.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/30/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
6/28/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Hold |
5/28/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
5/9/2024 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
5/9/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
5/9/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
5/9/2024 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Hold | Hold |
5/8/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
5/8/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
5/6/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
4/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
4/11/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Sell | Strong Sell |
3/5/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/22/2024 | Not Identified | Not Identified | Hold | Hold |
2/15/2024 | Not Identified | Not Identified | Not Available | Hold |
2/8/2024 | Not Identified | Not Identified | Hold | Hold |
1/29/2024 | Evercore Partners | Liisa A Bayko | Hold | Hold |
12/19/2023 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
11/7/2023 | Not Identified | Not Identified | Hold | Hold |
11/7/2023 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
11/7/2023 | Not Identified | Not Identified | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 28 |
Average Target Price | $86.95 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -1.37 |